Yew Bio-Pharm Group
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Yew Bio-Pharm Group generated cash of $17,340,086, which is more than the previous year. Cash used in financing activities reached the amount of -$14,478 last year. Net change in cash is therefore -$178,502.
Cash Flow
| 2012 | 418.56K | -706.04K | -63.29K |
|---|---|---|---|
| 2013 | 4.44M | -3.69M | -210 |
| 2014 | 4.11M | -2.44M | -2.33M |
| 2015 | -1.37M | -2.36M | 3.96M |
| 2016 | 643.03K | 234.91K | -1.26M |
| 2017 | -2.62M | -799.07K | 3.92M |
| 2018 | 32.46M | -32.80M | 26.33K |
| 2019 | 11.95M | -14.66M | 2.90M |
| 2020 | 17.34M | -17.35M | -14.47K |
YEWB Cash Flow Statement (2012 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 742.29K | 521.67K | 859.83K | 278.99K | 681.60K | 487.94K | 1.15M | 386.82K | 732.37K |
Operating activities | |||||||||
Net income | 1.46M | 985.50K | -1.32M | 3.21M | 2.00M | 5.28M | 4.28M | 3.89M | 2.20M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 2.81M | 1.82M | 11.04M | 3.74M | 8.93M | 7.74M | 682.80K | 561.51K | 563.83K |
Stock-based compensation expense | 0 | 284.46K | 1.06M | 709.38K | 31.46K | 967.74K | 166.22K | 0 | 2.24M |
| Deferred income tax benefit | 0 | 284.46K | 1.06M | 709.38K | 31.46K | 967.74K | 166.22K | 0 | 2.24M |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | -775.54K | -1.68M | 18.51M | -8.55M | -11.34M | -3.11M | -506.81K | 323.16K | -722.17K |
Inventories | 2.73M | 3.58M | -6.07M | 850.35K | -4.08M | -5.73M | -842.55K | -222.73K | -2.09M |
Accounts payable | -113.72K | -119.75K | -235.60K | -2.93M | 2.80M | 11.84K | 0 | -1.00K | -1.36M |
Cash generated by operating activities | 17.34M | 11.95M | 32.46M | -2.62M | 643.03K | -1.37M | 4.11M | 4.44M | 418.56K |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -17.35M | -14.68M | -32.80M | -799.07K | -61.50K | -2.04M | -2.45M | -3.69M | -313.90K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -17.35M | -14.66M | -32.80M | -799.07K | 234.91K | -2.36M | -2.44M | -3.69M | -706.04K |
Financing activities | |||||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 65.85K | 335.39K | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -11.93M | 0 | -9.02M | 0 | -3.02M | 0 | 0 | 0 | 0 |
Cash used in financing activities | -14.47K | 2.90M | 26.33K | 3.92M | -1.26M | 3.96M | -2.33M | -210 | -63.29K |
Net Change In Cash | -178.50K | 220.62K | -338.16K | 580.83K | -402.61K | 193.66K | -671.67K | 772.79K | -345.55K |
Cash at end of period | 563.79K | 742.29K | 521.67K | 859.83K | 278.99K | 681.60K | 487.94K | 1.15M | 386.82K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |